All In Biotech

Drug Trial Radar · NCT00402363

Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation

Last checked: Nov 20, 2026Latest source record: Jan 30, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 663 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

663

Actual

Start

Nov 2006

Primary completion

Jan 2010

Study completion Jan 2010

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 22, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate efficacy and safety of Omacor (omega-3-acid ethyl esters) in patients with recurrent, symptomatic atrial fibrillation.

Conditions

  • Fibrillation, Atrial

Interventions

  • omega-3-acid ethyl estersDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Paroxysmal AF With an Event of Documented Symptomatic Atrial Fibrillation (AF)/FlutterTime frame: From first dose of study drug (Day 1) to the first symptomatic recurrence of AF/flutter (up to Week 24)

Locations

178 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Huntsville, Alabama

  • GSK Investigational Site

    Anchorage, Alaska

  • GSK Investigational Site

    Cottonwood, Arizona

  • GSK Investigational Site

    Mesa, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Fort Smith, Arkansas

  • GSK Investigational Site

    Hot Springs, Arkansas

  • GSK Investigational Site

    Alamada, California

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Beverly Hills, California

  • GSK Investigational Site

    Carmichael, California

  • GSK Investigational Site

    Fair Oaks, California

  • GSK Investigational Site

    Fountain Valley, California

  • GSK Investigational Site

    Loma Linda, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Merced, California

  • GSK Investigational Site

    Palm Springs, California

  • GSK Investigational Site

    Poway, California

  • GSK Investigational Site

    Redondo Beach, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Vista, California

  • GSK Investigational Site

    Walnut Creek, California

  • GSK Investigational Site

    Aurora, Colorado

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Littleton, Colorado

  • GSK Investigational Site

    Bridgeport, Connecticut

  • GSK Investigational Site

    Farmington, Connecticut

  • GSK Investigational Site

    Guilford, Connecticut

  • GSK Investigational Site

    Washington D.C., District of Columbia

Showing 40 of 178 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.